These Analysts Cut Their Forecasts On BridgeBio Oncology After Q3 Results

BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) on Tuesday posted a narrower-than-expected loss for the third quarter.

The company reported quarterly losses of 43 cents per share which beat the analyst consensus estimate of losses of 69 cents per share.

“The third quarter was an important period for BBOT as we reported updated clinical data for BBO-8520 and delineated our strategic focus. Driven by encouraging clinical data across all three programs we are executing on multiple combinations with the potential for significant patient benefit,” said Pedro J. Beltran, Ph.D., Chief Executive Officer of BBOT. “With a strong balance sheet, multiple data catalysts expected through mid-2027, and cash runway into 2029, we believe BBOT is well positioned to advance differentiated therapies for patients with KRAS-driven cancers.”

BridgeBio Oncology shares gained 18% to trade at $2.5950 on Wednesday.

These analysts made changes to their price targets on BridgeBio Oncology following earnings announcement.

• Wedbush analyst David Nierengarten maintained the stock with an Outperform rating and lowered the price target from $25 to $9.
• Piper Sandler analyst Biren Amin maintained the stock with an Overweight rating and cut the price target from $21 to $15.

Considering buying BBOT stock? Here’s what analysts think:

Photo via Shutterstock